NZ630255A - Injectable preparation comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof - Google Patents

Injectable preparation comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof

Info

Publication number
NZ630255A
NZ630255A NZ630255A NZ63025513A NZ630255A NZ 630255 A NZ630255 A NZ 630255A NZ 630255 A NZ630255 A NZ 630255A NZ 63025513 A NZ63025513 A NZ 63025513A NZ 630255 A NZ630255 A NZ 630255A
Authority
NZ
New Zealand
Prior art keywords
benzo
butoxy
salt
quinolin
thiophen
Prior art date
Application number
NZ630255A
Other languages
English (en)
Inventor
Takuya Minowa
Tetsuya Sato
Yusuke Hoshika
Hidekazu Toyofuku
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49483139&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ630255(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of NZ630255A publication Critical patent/NZ630255A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ630255A 2012-04-23 2013-04-23 Injectable preparation comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof NZ630255A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636932P 2012-04-23 2012-04-23
US201361791896P 2013-03-15 2013-03-15
PCT/JP2013/061950 WO2013161830A1 (ja) 2012-04-23 2013-04-23 注射製剤

Publications (1)

Publication Number Publication Date
NZ630255A true NZ630255A (en) 2016-05-27

Family

ID=49483139

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ630255A NZ630255A (en) 2012-04-23 2013-04-23 Injectable preparation comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof

Country Status (31)

Country Link
US (6) US20150086632A1 (enExample)
EP (1) EP2868318B2 (enExample)
JP (1) JP6249944B2 (enExample)
KR (1) KR102168263B1 (enExample)
CN (4) CN110638752A (enExample)
AR (1) AR090775A1 (enExample)
AU (1) AU2013253518B2 (enExample)
BR (1) BR112014026398B1 (enExample)
CA (1) CA2871398C (enExample)
CO (1) CO7151499A2 (enExample)
CY (1) CY1123195T1 (enExample)
DK (1) DK2868318T4 (enExample)
EA (1) EA026124B1 (enExample)
ES (1) ES2727454T5 (enExample)
HR (1) HRP20190841T4 (enExample)
HU (1) HUE043686T2 (enExample)
IL (1) IL235211A0 (enExample)
IN (1) IN2014DN08870A (enExample)
JO (1) JO3524B1 (enExample)
LT (1) LT2868318T (enExample)
MX (1) MX361722B (enExample)
MY (1) MY169099A (enExample)
NZ (1) NZ630255A (enExample)
PH (1) PH12014502366B1 (enExample)
PL (1) PL2868318T5 (enExample)
PT (1) PT2868318T (enExample)
SG (2) SG10201608684QA (enExample)
SI (1) SI2868318T2 (enExample)
TW (1) TWI641395B (enExample)
UA (1) UA118084C2 (enExample)
WO (1) WO2013161830A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
TWI562991B (en) 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
CN112402421A (zh) * 2012-10-25 2021-02-26 大塚制药株式会社 含有依匹唑派或其盐的预防和/或治疗剂
WO2017106641A1 (en) * 2015-12-17 2017-06-22 Assia Chemical Industries Ltd. Solid state forms of brexpiprazole
US10501450B2 (en) 2016-02-01 2019-12-10 Hexal Ag Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations
WO2017208251A1 (en) * 2016-05-31 2017-12-07 Cipla Limited A new stable polymorph of brexpiprazole and process for preparation thereof
WO2018033484A1 (en) 2016-08-16 2018-02-22 Hexal Aktiengesellschaft Pharmaceutical compositions of a benzothiophene compound
EP3577111A1 (en) 2017-02-02 2019-12-11 Hexal Aktiengesellschaft Crystalline brexpiprazole
KR20210144810A (ko) * 2019-03-28 2021-11-30 오츠카 세이야쿠 가부시키가이샤 벤조아제핀 화합물-함유 동결건조 조성물
JPWO2021029020A1 (enExample) * 2019-08-13 2021-02-18
JP2024533933A (ja) * 2021-09-07 2024-09-18 シチュアン ケルン ファーマシューティカル リサーチ インスティテュート カンパニー リミテッド 注射用持続型ブレクスピプラゾール製剤およびその調製方法
CN117214053A (zh) * 2023-10-17 2023-12-12 海南卫康制药(潜山)有限公司 一种注射用头孢呋辛钠肌注混悬液的粒度测定方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3402195B2 (ja) * 1997-05-14 2003-04-28 千寿製薬株式会社 再分散性の良い水性懸濁液剤
EP0995435B1 (en) 1997-05-14 2007-04-25 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations with excellent redispersibility
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
JP5000835B2 (ja) 2000-08-25 2012-08-15 千寿製薬株式会社 水性懸濁液剤
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
BRPI0415531B8 (pt) * 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
WO2007035348A2 (en) 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
TW200808375A (en) 2006-05-12 2008-02-16 Otsuka Pharma Co Ltd Hydrogel suspension and manufacturing process thereof
TWI415629B (zh) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
LT2170279T (lt) 2007-07-31 2018-03-12 Otsuka Pharmaceutical Co., Ltd. Aripiprazolo suspensijos ir liofilizuotos kompozicijos gamybos būdai
RU2481842C2 (ru) * 2008-03-11 2013-05-20 Алькон Рисерч, Лтд. Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций
NZ592984A (en) * 2008-11-19 2012-12-21 Merial Ltd Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol
JP5575269B2 (ja) * 2010-08-24 2014-08-20 大塚製薬株式会社 カルボスチリル誘導体並びにシリコーンオイル及び／又はシリコーンオイル誘導体を含有する懸濁液及びケーキ組成物
US9469630B2 (en) * 2010-10-18 2016-10-18 Sumitomo Dainippon Pharma Co., Ltd. Sustained-release formulation for injection
ES2972387T3 (es) * 2011-03-18 2024-06-12 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de sorbitán
JP2012232958A (ja) 2011-05-09 2012-11-29 Otsuka Pharmaceut Co Ltd 注射製剤
US9999670B2 (en) * 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Also Published As

Publication number Publication date
CN111888329A (zh) 2020-11-06
SG10201608684QA (en) 2016-12-29
KR102168263B1 (ko) 2020-10-21
IN2014DN08870A (enExample) 2015-05-22
HRP20190841T4 (hr) 2022-03-04
CN110638752A (zh) 2020-01-03
SI2868318T1 (sl) 2019-06-28
US20180092910A1 (en) 2018-04-05
MX361722B (es) 2018-12-14
AU2013253518B2 (en) 2017-10-05
PT2868318T (pt) 2019-06-07
AR090775A1 (es) 2014-12-03
EA201491937A1 (ru) 2015-03-31
ES2727454T3 (es) 2019-10-16
TW201406401A (zh) 2014-02-16
EP2868318A1 (en) 2015-05-06
CA2871398A1 (en) 2013-10-31
HK1205678A1 (en) 2015-12-24
WO2013161830A1 (ja) 2013-10-31
JP6249944B2 (ja) 2017-12-20
IL235211A0 (en) 2014-12-31
EP2868318B1 (en) 2019-03-06
ES2727454T5 (es) 2022-05-13
US20240277702A1 (en) 2024-08-22
JO3524B1 (ar) 2020-07-05
CN104363912A (zh) 2015-02-18
HUE043686T2 (hu) 2019-09-30
PH12014502366A1 (en) 2015-01-12
EA026124B1 (ru) 2017-03-31
UA118084C2 (uk) 2018-11-26
PL2868318T5 (pl) 2022-06-20
US20220305007A1 (en) 2022-09-29
CA2871398C (en) 2021-04-27
CO7151499A2 (es) 2014-12-29
EP2868318A4 (en) 2015-12-09
US20250241909A1 (en) 2025-07-31
MY169099A (en) 2019-02-18
MX2014012734A (es) 2015-04-10
DK2868318T4 (da) 2022-03-28
TWI641395B (zh) 2018-11-21
LT2868318T (lt) 2019-07-25
SI2868318T2 (sl) 2022-04-29
PH12014502366B1 (en) 2015-01-12
CN107536802A (zh) 2018-01-05
SG11201406775UA (en) 2014-12-30
BR112014026398A2 (pt) 2017-06-27
US20150086632A1 (en) 2015-03-26
BR112014026398B1 (pt) 2022-11-29
US20200163960A1 (en) 2020-05-28
AU2013253518A1 (en) 2014-11-06
EP2868318B2 (en) 2022-01-26
HRP20190841T1 (hr) 2019-07-26
DK2868318T3 (da) 2019-06-03
JPWO2013161830A1 (ja) 2015-12-24
US10624889B2 (en) 2020-04-21
PL2868318T3 (pl) 2019-09-30
KR20150003336A (ko) 2015-01-08
CY1123195T1 (el) 2021-10-29

Similar Documents

Publication Publication Date Title
JOP20210047A1 (ar) عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
ZA201402333B (en) Tablet including 7-[4-(4-benzo[b]thiophen-4-yl-piperazin -1-yl)butoxy]-1h-quinolin-2-one or salt thereof
CA2865011C (en) Methods and compositions for treating huntington's disease
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
MX348823B (es) Formulaciones estables de linaclotida.
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
MX2015012005A (es) Inhibidores de bromodominio.
MX2014006136A (es) Uso de aril- y hetarilcarboxamidas como endoparasiticidas.
MA44637A1 (fr) Composes hétérocycliques et leurs utilisations
SG11201404595TA (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
IN2015DN03984A (enExample)
ZA201509016B (en) Compositions, methods & systems for respiratory delivery of three or more active agents
NZ730571A (en) Pharmaceutical compositions having improved storage stability
EP2888373A4 (en) ANTIBODY AGAINST ARIPIPRAZOLE AND USE THEREOF
PH12014502366A1 (en) Injectable formulation
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PL402710A1 (pl) Kompozycje farmaceutyczne zawierajace imatinib lub jego farmaceutycznie dopuszczalna sól oraz sposoby ich otrzymywania
EP2987786A4 (en) AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE
IL230484A (en) "6- (n- (7-Chloro-1-Hydroxy-1, 3-Dihydrobenzo [c] [1,2] Oxaborol-5-Yl) - Methylbenzoforan-3 - Carbamamide and a Pharmaceutical Preparation
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
MD20120079A2 (en) Pharmaceutical including benzyldimethyl(3-[myristoylamino]propyl)-ammonium chloride and its use for the treatment and prevention of infectious and pyoinflammatory diseases of different etiology and localization
MX2014013496A (es) 5-halopirazol benzofuranil carboxamidas.
WO2013158773A3 (en) Rnase 7 antimicrobial peptides
IN2014DN11044A (enExample)
EP2738174A4 (en) NEW PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE INGREDIENTS

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2018 BY CPA GLOBAL

Effective date: 20170324

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2019 BY CPA GLOBAL

Effective date: 20180309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2020 BY CPA GLOBAL

Effective date: 20190307

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2021 BY CPA GLOBAL

Effective date: 20200312

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2022 BY CPA GLOBAL

Effective date: 20210312

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2023 BY CPA GLOBAL

Effective date: 20220310

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2024 BY CPA GLOBAL

Effective date: 20230309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240308

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250307

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2027 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20260312